(Fighting New Coronary Pneumonia) Russia Registers "Satellite LIGHT" New Coronary Vaccine
China News Service, Moscow, May 6 (Reporter Wang Xiujun) The Russian Direct Investment Fund ("Satellite-V" vaccine co-producer) announced on the 6th that Russia has registered the new crown vaccine "Satellite LIGHT".
"Satellite LIGHT" was developed by the National Research Center of Epidemiology and Microbiology of Gamallea. Compared with "Satellite-V", the "Satellite LIGHT" vaccine can produce antibodies in a shorter time with one injection.
On February 27, the Ministry of Health approved the Phase III clinical trial of "Satellite LIGHT".
Phase III clinical trials were carried out in 15 medical institutions in Moscow, Kaliningrad, St. Petersburg and other places, with a total of about 4,000 volunteers participating.
According to the news, the effectiveness of the "satellite LIGHT" vaccine reached 79.4% 28 days after vaccination, and there were no serious side effects among the testers.
According to the news, the cost of injecting a "satellite LIGHT" vaccine in foreign markets will be less than US$10, and its storage range is from minus 2 degrees Celsius to minus 8 degrees Celsius, and the logistics requirements are very simple.
Prior to this, Russia has registered the "Satellite-V" vaccine developed by the National Research Center for Epidemiology and Microbiology of Gamallea, the "EpiVacCorona" vaccine developed by the "Vector" National Science Center for Virology and Biotechnology, and the Chumakov Federal Immunization And the "Kovivac" vaccine developed by the Biological Products Research and Development Research Center.
(Finish)